• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

by Elena Iemma | May 28, 2025 | News

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO PROVIDENCE, R.I., May 28, 2025 /PRNewswire/ — EpiVax, Inc., a leader in preclinical immunogenicity assessment for biologic therapeutics and vaccines, is pleased to announce the...
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies

by Elena Iemma | Apr 21, 2025 | News

The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies PROVIDENCE, R.I., April 21, 2025 /PRNewswire/ — EpiVax, Inc. announces a new study published in Frontiers in Immunology unveiling...
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

by Elena Iemma | Feb 27, 2025 | News

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements PROVIDENCE, R.I., Feb. 27, 2025 — EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax’s immunoinformatics team in 2014 and...
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

by Elena Iemma | Dec 9, 2024 | News

PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth....
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

Supporting Health Equity: EpiVax Highlights Partnerships and New Research from Clínica Esperanza and GAIA Vaccine Foundation

by Elena Iemma | Dec 6, 2024 | News

PROVIDENCE, R.I., Dec. 6, 2024 — EpiVax, a leader in biotechnology known for its advanced immunoinformatics tools, proudly announces its continued support for two nonprofits, Clínica Esperanza/Hope Clinic and GAIA Vaccine Foundation....
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

by Elena Iemma | Oct 24, 2024 | News

PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ — EpiVax, Inc. and CUBRC, Inc. announce today that they have been awarded a two-year, $2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug...
« Older Entries

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar
  • Is “Artificial” Intelligence an Option for your ADA ?

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.AcceptDecline